8-Kfiled August 8, 2025, 7:59 PM ETticker CDTCIK 0001896212
other materialconfidence highsentiment neutralmateriality 0.65
Conduit renames to CDT Equity Inc., appoints James Bligh permanent CFO, adds 2M shares to incentive plan
CDT Equity Inc.
Name change from Conduit Pharmaceuticals Inc. to CDT Equity Inc. effective Aug 5, 2025; ticker remains CDT; no shareholder vote required.
James Bligh, co-founder and interim CFO since May 2024, appointed permanent CFO; compensation unchanged; retains board seat.
Stockholders approved amendment to 2023 Stock Incentive Plan adding 2,000,000 authorized shares for awards.
Press release details strategic shift: AI-driven drug repurposing via Sarborg partnership, animal health collaboration with Manoira, and evaluation of cryptocurrency treasury reserve strategy.
All five director nominees elected: Andrew Regan, Freda Lewis-Hall, James Bligh, Chele Chiavacci Farley, Simon Fry; auditor CBIZ CPAs P.C. ratified.
CDT Equity Inc.: Amended certificate of incorporation to change company name from Conduit Pharmaceuticals Inc. to CDT Equity Inc (effective 2025-08-05).
Change
charter amendment
Effective
2025-08-05
Exact text from the filing
On August 5, 2025, the Company filed an amendment to its Second Amended and Restated Certificate of Incorporation (the “ Certificate of Incorporation ”), to effect a change of the Company’s name from “Conduit Pharmaceuticals Inc.” to “CDT Equity Inc.” (the “ Name Change ”), which became effective at 5 p.m. Eastern Time on August 5, 2025.
CDT Equity Inc.: Amended and restated bylaws to reflect name change and update quorum description per a prior amendment (effective 2025-08-05).
Change
bylaw amendment
Effective
2025-08-05
Exact text from the filing
In connection with the Name Change, the Company also amended and restated its Amended and Restated Bylaws (as amended, the “ Second Amended and Restated Bylaws ”) on August 5, 2025 to reflect the Name Change.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.